Most events on this list can be tied to a specific page
somewhere on the internet. List entries contain links to such pages
through the "Details". Occasionally events have no such page or the information on
it is inadequate.
In such cases I attempt to cobble together a details page myself.
“A Simple, One-Time, Inexpensive and Non-Toxic Intervention to Improve Cancer Survival,” by Dr. Vikas P. Sukhatme.
When: Tuesday, December 8, 2015 from 5:00-6:00pm, with a reception immediately following
Where: E51-345, located on the third floor at 2 Amherst Street in Cambridge, MA (http://whereis.mit.edu/?go=E51).
If you are interested in attending, please reply to Jennifer Grady
Description: Lung cancer is sometimes diagnosed in its early stages yet despite
surgery, radiation, and chemotherapy, these tumors often recur systemically and
lead to death. Retrospective data show that a pre-operative single dose of an
existing therapeutic used off-label tended to increase metastasis-free survival
over 10 years by about 15%. If proven, this simple, inexpensive, and non-toxic
intervention could save the lives of nearly 5,000 lung cancer patients and half
a billion dollars in healthcare costs annually in the US alone. However, with
today’s drug development model it will never be adopted as standard of care—with
little to gain financially, pharmaceutical companies have little interest in
sponsoring the prospective trial necessary to validate the data. GlobalCures, a
non-profit medical research organization, exists to fill this gap and its model
will be presented.
Biography: Vikas P. Sukhatme MD ScD is the Victor Aresty Professor of Medicine
at Harvard Medical School and Chief Academic Officer at Beth Israel Deaconess
Medical Center. As a physician-scientist, Dr. Sukhatme has had a longstanding
interest in cancer. Current investigations in his laboratory center on tumor
metabolism and immunology. He is recognized for interdisciplinary clinical and
basic science research: elucidating mechanisms of statin-induced myopathy, tumor
angiogenesis and sepsis and as part of the team that discovered the cause of
preeclampsia. He has conducted studies on genes important in kidney cancer and
polycystic kidney disease. His laboratory cloned the first family of mammalian
zinc finger transcription factors, the most common motif in the human genome.
Finally, he is a co-founder of a not-for-profit organization, GlobalCures, whose
goal is to conduct clinical trials on promising therapies for cancer not being
pursued for lack of profitability. Closely related to this effort, he is also
spearheading efforts to establish a cancer clinic that uses novel drug
combinations off-label for those who have run out of options.
About GlobalCures: GlobalCures is a non-profit medical research organization
that is advancing clinical research on scientifically promising, readily
available, and cost-effective treatments that otherwise would not be pursued
because they are “financial orphans.” Financial orphans are therapies for which
there are no financial incentives for pharmaceutical companies to develop them,
in this case, for cancer treatment. These include off-patent generic drugs that
are FDA approved to treat non-cancer indications. Visit the GlobalCures website